The amelioration of T2DM rat femoral bone achieved by anti-osteoporosis of caprine CSN1S2 protein through bone morphogenetic protein signaling pathway

Fatchiyah Fatchiyah1,2✉, Bambang Setiawan3, Tomohiko Sasase4 and Takeshi Ohta5

1Research Center of Smart Molecule of Natural Genetics Resource, Brawijaya University, Malang, East Java, Indonesia; 2Department of Biology, Faculty of Mathematics and Natural Sciences, Brawijaya University, Malang, East Java, Indonesia; 3Department of Biochemistry and Molecular Biology, Medical Faculty, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia; 4Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan; 5Graduate School of Agriculture, Kyoto University, Kyoto, Japan.

We investigated the potential anti-glycation and anti-osteoporosis properties of Caprine milk CSN1S2 protein on the serum AGEs and sRAGE level, femoral bone mesostructure, histomorphometry, and hydroxyapatite crystals changes in T2DM rats. Varying doses of Caprine milk CSN1S2 protein (0, 375, 750, and 1500 mg/kg BW) were used to treat the control and T2DM rats. We measured AGEs and sRAGE level; RUNX2, OSX, BMP2, and Caspase-3 expressions in rats using ELISA and immunohistochemistry, respectively. The mesostructure and histomorphometry of femoral bone was analyzed using SEM Microscope and BoneJ software, then hydroxyapatite crystal size was determined using SEM-XRD. T2DM rats showed a high level of AGEs and a low level of sRAGE, the RUNX2, OSX, and BMP2 expression was down regulated, BV, BV.TV, Tb.Th, Tb.Sp, increased and SMI levels declined, respectively. Vice versa, after administration of the CSN1S2 protein to T2DM rats, improvement in all levels of molecular and cellular markers was achieved. In the CSN1S2 highest dose, AGEs level declined and sRAGE level elevated in T2DM rats. The 375 and 750 mg/kgBW of CSN1S2 protein was able to upregulate the RUNX2, OSX, and BMP2 expression in T2DM rats, thus improving the normalization of osteoclasts and osteoblasts number. The whole dose of CSN1S2 triggered the thickening of trabecular bone wall, granule formation, and normalized the trabecular thickness (Tb.Th) parameter of T2DM rats. The hydroxyapatite crystal size was increased in the highest dose of CSN1S2-treated T2DM rats. This study indicated that CSN1S2 protein had a protective effect against osteoporosis in the T2DM rat bones by means of glycation pathway inhibition, bone histomorphometry and mesostructure improvement via bone morphometric protein signaling.

Keywords: AlphaS2-casein, bone, diabetes, BMP signaling: mesostructure, osteoporosis

Received: 24 November, 2020; revised: 06 January, 2021; accepted: 14 April, 2021; available on-line: 09 May, 2021

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a metabolic disease caused by insulin secretion abnormality that induces hyperglycemia. Hyperglycemia is a major factor in microvascular and macrovascular complications in diabetes mellitus. This complication may take place via the polyol pathways, dysregulation of protein kinase c, hexosamine pathways, and advanced glycation end products (AGEs) (Gateva et al., 2019). The AGEs are diverse compounds formed by non-enzymatic glycation reactions of proteins, lipids, and nucleic acids. The glycation reaction includes several stages, namely the reversible bond between the carbonyl group of reducing sugar and the amino-terminal group of proteins, lipids, or nucleic acids forming the Schiff base. The rearrangement of the Schiff base will establish more stable ketoamines, which are called Amadori products. These products have structural changes through oxidation, dehydration, and degradation to produce AGEs compound with high stability (Stirban et al., 2014).

The interaction of AGEs and the AGEs receptor (RAGEs) plays an important role in the diabetes complications pathway (Devangelio et al., 2007). In patients with T2DM, there was no increase in serum AGEs and trabecular bone AGEs level compared to control. However, cortical bones AGEs levels were elevated significantly compared to control (Karim et al., 2018). Accumulated AGEs in bones will bind to their receptors in osteoblasts and osteoclasts. AGEs-RAGE binding will increase osteoclast activity and reduce osteoblast activity thereby contributing to resorption and bone fragility (Okazaki & Yamaguchi, 2012; Willett et al., 2014). The osteoblastogenesis is initiating by the bone morphogenetic proteins (BMPs) signaling pathway, which is a fundamental role in bone formation and development. Dysregulation of BMP signal transduction causes the bone disorder on skeletal differentiation and development (Wu et al., 2016). Moreover, the BMPs have a positive effect on chondrogenesis and cartilage formation through SMAD-dependent signaling (Thielen et al., 2019). The BMPs stimulated the expression of runt-related tran-
scription factor 2 (RUNX2) and osteix (OSX) capable of inducing the differentiation of mesenchymal cells into osteoblasts (Hie et al., 2011). The BMPs, RUNX2, and OSX expressions are affected by the increasing of AGEs levels in high glucose-treated human osteoblasts and diabetic rats (Miranda et al., 2016; Pickel et al., 2019; Wu et al., 2019).

In general, the dimensions, mineral density, and microarchitecture measurements characterized bone quality. All these factors are influenced by the rate of bone turnover (Seeman & Delmas, 2006). The relationship between bone mineral density and T2DM is unclear. There is an increase, decrease, or no change in bone volume in T2DM (Adil et al., 2015; Issa et al., 2011; Takizawa et al., 2003). Cortical T2DM was found to increase porosity (Kazakia et al., 2010; Campbell et al., 2016), the effect on the trabecular was unknown and would be assessed in this study. In patients with type2 diabetes, there is an increase in trabecular thickness (Kazakia et al., 2010). High fat diet administrated-rats develop an insulin resistance causing lowered compact bone and stiffness that associated with bone fragility (Yamanaka et al., 2018). Skeletal fragility is a major complication of T2DM. Nevertheless, the mechanism of skeletal fragility is still not understood. Increased risk of fracture is deemed to be an effect of microarchitecture worsening or poor bone quality caused by the AGEs accumulation. There is still controversy about the role of AGEs in bone. In the ex vivo study, there was a negative correlation between AGEs with ultimate strain and stress of cortical and trabecular bone (Nyman et al., 2007; Karim & Vashishth, 2012). Previous studies had found no association between AGEs and trabecular biomechanical properties (Burt-pichat et al., 2011). Serum AGEs correlate with AGEs in trabecular bone (Karim et al., 2018). Other studies proved that the AGEs accumulation can alter the bone organic matrix, trigger growth and crack propagation (Poundarik et al., 2015). Osteoclasts resorption activities were correlated with the in situ concentration of AGEs positively (Dong et al., 2011). However, there are still opposing opinions among their research.

The AGE-RAGE interaction blockade can be achieved by soluble RAGE (sRAGE), which is naturally produced by alternative splicing of RAGE mRNA. The sRAGE is a splice variant of the full-length receptor. The sRAGE circulates in the plasma naturally and represent as an enticement to inhibit the binding of AGEs-RAGE (Devangelio et al., 2007). The T2DM patients had significantly lower levels of plasma sRAGE than control (Abdulle et al., 2019). The diabetes animal model also demonstrated a decrease of sRAGE levels (Hsia et al., 2016). On the contrary, several studies had investigated the existence of sRAGE levels increase in T2DM (Kerkeni et al., 2012). The sRAGE is protective in preventing bone loss in alveolar diabetic mice (Lalla et al., 2000).

The emergence of AGEs is an important factor in diabetes so that the strategies development against AGEs has been in the center of scientific interest. The strategies include developing substances such as the AGE formation inhibitor, AGE breakers, and nutraceuticals as well (Gkogkolou & Böhm, 2012). Goat milk contains alpha-S2 casein (CSN1S2) protein that has a lot of biological function potency to control some mechanisms. Our previous research found that CSN1S2 has a wide range of food safety (Agustina et al., 2015) and has potential as a therapeutic agent in the diabetic rat model at the level of a molecular mechanism (Fatchiyah et al., 2020). It has an anabolic effect on bone through a crystallization mechanism and mesostructure improvement in the rat rheumatoid arthritis model. It is able to modulate RAGE expression as well (Bia et al., 2015; Fatchiyah et al., 2015). Moreover, CSN1S2 is capable of triggering proliferation in pre-osteoblast cells induced by methylglyoxal (Chotima et al., 2015). We predict that Caprine CSN1S2 protein functions as a functional protective food to control the mechanism pathway related to the bone fragility, as anti-glycation, and anti-osteoporosis. Therefore, this study focused to analyze the role of CSN1S2 in the glycation pathway, mesostructure, histomorphometry, and hydroxyapatite crystal changes in T2DM rat femoral bone.

MATERIALS AND METHODS

Preparation of CSN1S2 protein from Ethawah crossbred goat milk

The Ethawah crossbred goat milk (250 mL) was heated to the temperature of 40°C, followed by the addition of glacial acetic acid (5 mL) until precipitate formed. Protein was filtered using nylon membranes to obtain the precipitate. The protein obtained was quantified by the UV-Vis NanoDrop spectrophotometer. The protein was stored at −20°C for subsequent analysis. The 36kDa CSN1S2 protein was isolated and cut from SDS-PAGE gel and then purified using the previous protocol (Bia et al., 2015). Purified-CSN1S2 protein was stored at −20°C until used.

T2DM rat model establishment

In this study, we used forty-three-month-old adult male rats (Rattus norvegicus) of the Wistar strain, weighing 100–150 grams, acclimated to laboratory conditions for a week. The experimental animals were obtained from Integrated Research and Testing Laboratory, Gadjah Mada University, Yogyakarta, Indonesia. The rats were given standard diet which contained cornstarch, wheat bran, palm oil, essential amino acids, minerals, and vitamins (Comfeed PARS, JAPFA Comfeed Indonesia, Tbk.). This standard diet was given during the acclimatization period and during the research process in T2DM and control rats (normal rats). To make the twelve of T2DM rats’ model, the T2DM rats were established by high cholesterol (45–50% standard diet, 20–30% wheat flour, 3–6% duck egg yolk, 10–20% goat fat, 2–3% coconut oil, 0.1–0.5% choline acid) feeding for 2 months until they had hypercholesteremia (cholesterol levels >200 mg/dl). Then, the positive high-cholesterol rats were injected with 25 mg/kg BW of streptozotocin (STZ) intraperitoneally. After the STZ injection, blood glucose levels were monitored every 2 weeks. DM is diagnosed when blood sugar exceeds 250 mg/dl (Moree et al., 2013). The blood glucose and cholesterol parameters were evaluated by NescoMultiCheck (biop tik Technology, Taiwan).

The treatment of CSN1S2 protein in the experimental rat

The forty rats were divided into 8 groups with 5 rats per each group. The groups include 4 groups of control (C) rats and 4 groups of T2DM (DM) rats. We treated the control and T2DM rats with several doses of Caprine milk CSN1S2 protein (0, 375, 750, and 1500 mg/kg BW). Therefore, there were eight groups of experiment: control rat group without adding CSN1S2 protein (C), control rat group receiving 375 mg/kg BW of CSN1S2 protein (CM375), control rat group receiving 750 mg/kg
BW of CSN1S2 protein (CM750), control rat group receiving 1500 mg/kg BW of CSN1S2 protein (CM1500), T2DM rat group without adding the CSN1S2 protein (DM), T2DM rat group receiving 375 mg/kg BW of CSN1S2 protein (DMM375), T2DM rat group receiving 750 mg/kg BW of CSN1S2 protein (DMM750), and T2DM rat group receiving 1500 mg/kg BW of CSN1S2 protein (DMM1500). The CSN1S2 protein treatment was carried out orally (by oral gavage) one treatment per dose for 28 days.

**Surgical technique and organ isolation**

Euthanasia was performed using the standard protocol (Fatchiyah et al., 2006). The dead rats were dissected to obtain the tissue samples, including the femoral bone samples. Then, the femoral bone was incubated at 4% paraformaldehyde min. 24 h. After that, the femoral bone was embedded on paraffin block. The embedded bone tissue was cut by microtome around 5 μm and the bone tissue pieces were placed on histological slide.

**AGEs and sRAGE analysis**

The serum level of AGEs and sRAGE expressions were measured by Sandwich-ELISA method. We used ELISA assay kit (Elabcience Biotechnology, Sydney) and anti-rat AGEs and sRAGE antibodies (Bioassay Technology Laboratory, China). The analysis was carried out according to the kit protocol.

**Histopathological and immunohistochemistry analysis**

The histopathological profile of femoral bone tissue was observed from the hematoxylin and eosin (H&E) stained tissue section. The double staining immunohistochemistry was performed to analyze the RUNX2, OSX, BMP2, and Caspase-3 expressions in femoral bone (Fatchiyah et al., 2006). The tissue sections were deparaffinized in xylene and rehydrated in graded alcohol, then washed in PBS pH 7.4. After blocking with 2% skim milk for 1 hour, the sections were incubated with the first primary antibody for 1 hour in room temperature. The first primary antibodies used were the mouse anti-RUNX2 (Santa Cruz Biotechnology, USA with 1:1000 dilution) and mouse anti-BMP2 (Bioss, USA with 1:1000 dilution) in 1% skim milk. The sections were washed with PBS (pH 7.4) three times. They were incubated with the second primary antibody overnight at 4°C, and then washed in PBS (pH 7.4). The second primary antibodies used were the rabbit anti-OSX (Bioss, USA with 1:1000 dilution) and mouse anti-Caspase-3 (Santa Cruz Biotechnology, USA with 1:1000 dilution) in 1% skim milk. The sections were incubated with the following secondary antibodies: HRP-labelled goat anti-mouse IgG (1:1500) and AP-labels goat anti-rabbit IgG at room temperature for 1 hour and washed with PBS (pH 7.4). The sections were incubated with DAB and LV Blue substrate and washed in PBS pH 7.4. The femoral bone tissue sections were visualized and analyzed using light microscope FSX-100 (Olympus) with 200× magnifications. The osteoblast and osteoclast number were counted and the RUNX2, OSX, BMP2, and Caspase-3 expression levels were measured by FSX-BSW software.

**Femoral bone mesostructure**

The rat femoral bones were cut to size 2x2 x 1 millimeter, then immediately immersed in 2% glutaraldehyde in a 0.1 M cacodylate buffer (pH 7.4) at 4°C for 4 hours. They were decalcified with 5% EDTA and 0.2 M sucrose (pH 7.4) at 4°C for 48 hours. The post-fixation was done in osmium tetroxide 1% in a 0.1 M cacodylate buffer (pH 7.4). The bones were dehydrated and immersed in Luveak 812 resin. We used ultramicrotome to generate the bone sections of 70–80 nanometers thickness. The sections were stained with uranium acetate and lead citrate, then they were observed using Scanning Electron Microscopy (SEM) at the Physics Laboratory and Central Laboratory of Faculty of Science, Malang State University, Malang, Indonesia (Noor & Setiawan, 2013).

**Femoral bone histomorphometry**

Histomorphometry measurements of femoral bones were performed according to the previous study methods (Parfitt et al., 1987). The femur mesostructure analysis was performed at 70–80× magnifications. BoneJ software was used for histomorphometry analysis. There were several parameters measured in this study, including the bone volume (BV), trabecular bone volume (TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and structure model index (SMI). All formulas, symbols, units, and nomenclature were based on the guidelines from the American Society for Bone and Mineral Research (ASBMR) Histomorphometry Nomenclature Committee (Hofbauer et al., 2007).

**Femoral bone hydroxyapatite crystals**

Analysis of bone hydroxyapatite crystals was carried out as in the previous study. The bone ash was made by heating in 800°C for 2 hours with a muffle furnace (Hayatullina et al., 2012). We performed the characterization of the X-ray diffraction (XRD) of T2DM and control bone using PANalyticalX’Pert PRO-MPD. High Score Plus, Crystal Maker, and DDVIEW complemented with the latest version of PDF2 were utilized for subsequent analysis. Diffraction spectra were recorded at an angle of 29, from 20° to 60°, with a Cu Kα radiation source (wavelength = 1.54056 Å, 40 mA, 40 kV) and step size of 0.05°. The average sizes of apatite crystals in various groups were evaluated by the Scherrer equation. Rietveld refinement analysis was obtained from detailed spectra of T2DM and controlapatite samples (Noor & Setiawan, 2013).

**Ethics**

This study had been evaluated and approved by the Research Ethics Committee of Brawijaya University, Malang, and East Java, Indonesia (Certificate number, 417-KEP-UB).

**Statistical Analysis**

All data were tabulated, presented as mean ± standard deviation and group differences were analyzed by ANOVA followed by Duncan test with P value<0.05 (SPSS 16.0 Inc., Chicago, Illinois, USA). The significance of P<0.05 was concluded to be statistically significant.

**RESULTS**

The level of AGEs and expression of sRAGE in serum samples

The changes of AGEs level and sRAGE expression in CSN1S2-treated rats are shown in Fig. 1. A reduction of serum AGEs level took place in the control rats treated...
with 375 mg/kg BW, 750 mg/kg BW, and 1500 mg/kg BW of CSN1S2 protein. Diabetic rats turned out to have a significant rise in the serum AGEs level. This AGEs level was affected significantly by CSN1S2 protein administration. In this study, we investigated that the higher the dose of CSN1S2 protein given to diabetic rats, the lower the AGEs level. Hence, DMM1500 had the sharpest decrease in AGEs level. The Caprine CSN1S2 protein administration also had an impact on serum sRAGE expressions of rats. A significant increase of sRAGE expressions was observed in CM750 and CM1500 as compared to C group (p<0.05). On the contrary to AGEs level, the sRAGE expression of diabetic rats declined. CSN1S2 protein administered-diabetic rats showed an up-regulated expression of serum sRAGE. The highest rise of sRAGE expression occurred in DMM750.

The expression of RUNX2, OSX, BMP2 and Caspase-3 in all rat groups were related to the osteoclast and osteoblast number

The expressions of RUNX2, OSX, and BMP2 were extremely down regulated in diabetic rats compared to the control (Fig. 2; Fig. 6). The CSN1S2 protein treatment reduced the expression of RUNX2, OSX, and BMP2 in control rats although that was not significant. A different effect of this protein administration occurred to the diabetic rats. Three kinds of CSN1S2 protein doses were able to raise the OSX and BMP2 expression in diabetic rats (Fig. 3D and 3E). Moreover, the BMP2 expression of DMM750 was similar to the one in the control rat. In the case of RUNX2 expression, only the 1500 mg/kg BW of CSN1S2 protein had no effect on the diabetic rat. DMM375 and DMM750 had an up-regulated expression of RUNX2 (Fig. 3C). DM rat group resulted in the highest expression level of Caspase-3. In control rats, the administration of 375 mg/kg BW of CSN1S2 protein raised the Caspase-3 expression, while the 1500 mg/kg BW of CSN1S2 protein reduced it. CM750 had no change in its Caspase-3 expression compared to the C group. DMM375, DMM750, and DMM1500 showed a down-regulated expression of Caspase-3 (Fig. 3F).

The number of osteoclasts in Caprine CSN1S2 protein-treated control rats was not significantly different from the C group. The diabetic rats had a high number of osteoclasts. The administration of CSN1S2 protein at a dose of 375 and 750 mg/kg BW diminished the osteoclast number. However, the 1500 mg/kg BW of
CSN1S2 gave rise to the significant increase of diabetic rat’s osteoclast number (Fig. 3A).

There was a high number of osteoblasts in the control rats. This number was significantly reduced in the condition of diabetes. Interestingly, the 375 and 750 mg/kg BW of CSN1S2 protein were able to elevate the osteoblast number both in control and diabetic rats. When the rats received 1500 mg/kg BW of CSN1S2 protein, their osteoblast number was decreased (Fig. 3B).

Mesostructure of the femoral bone

The mesostructure of femur bone was observed at 200× and 2000× magnification. The control rat with 0 mg/kg BW CSN1S2 protein treatment (C) had rod-like trabeculae, minimal holes, and no granules. The trabecular bone surface of the C group was similar to the stepladder pattern (Fig. 4.I). The administration of CSN1S2 (375, 750, and 1500 mg/kg BW) to the control rats showed the thickening of the trabecular bone wall (Fig. 4.I). A flat trabecular bone surface without stepladder pattern was found in them. In addition, a high num-

![Figure 3. The cells number and expression level in osteogenic differentiation parameters.](image-url)
Number of granules were formed and fully filled in the holes of trabecular bone (Fig. 4.I and 4.III).

In diabetes mellitus rats, there was a thickening of the trabecular bone. The trabecular bone had a flat surface and cracks in several areas. Its holes were filled with a thickened bone and granules. DM group had a small number of granules and a thin trabecular bone wall. Interestingly, the bone thickening had not been found in the diabetic rat receiving 375 mg/kg of CSN1S2 (Fig. 4.I). The granules began to form in the trabecular bone hole of DMM375 and were still observed in the DMM750 and DMM1500. There was a trabecular bone wall thickening in DMM375, DMM750, and DMM1500. The granules formation and a thickened trabecular bone wall in them were almost similar to the control rats receiving three kinds of CSN1S2 doses (Fig. 4.III). Moreover, the trabecular bone holes were present in various locations of DMM750 and DMM1500 as well (Fig. 4.I).
The DMM375 had the layered topography of the trabecular bone surface. This layered topography was dominant in the trabecular bone surface of DMM750 and DMM1500 (Fig. 4.II).

Histomorphometry of the femoral bone

The Caprine CSN1S2 protein administration to the control rat significantly changed the histomorphometry parameters measured in this study (P<0.05), see Table 1. The bone volume, BV/TV, and trabecular thickness were decreased in control rat receiving 375 mg/kg BW and 750 mg/kg BW of CSN1S2 protein. The trabecular spacing of CM750 and CM1500 rat groups were lower than control. However, the Tb.Sp of CM375 was higher than the control rats with and without CSN1S2 treatment. The trabecular thickness of CM1500 rat group was higher than control, CM375, and CM750. We reported that diabetic rats had significant changes as compared to the control (P<0.05). They underwent an elevated value of BV, BV/TV, Tb.Th, and Tb.Sp. The BV, BV/TV, Tb.Th, and Tb.Sp of diabetic rats turned to decrease as the 375 mg/kg BW of CSN1S2 was administered. In the 750 mg/kg BW and 1500 mg/kg BW of CSN1S2 treatment, the diabetic rats had a lowered Tb.Th and Tb.Sp. Interestingly the CSN1S2 of 1500 mg/kg BW administration significantly raised the BV and BV/TV of diabetic rats compared with the control or DM group.

Hydroxyapatite crystal of the femoral bone

The hydroxyapatite crystals size of CM375 and CM1500 were bigger than that of C group (P<0.05) (Fig. 5). However, diabetes mellitus rats demonstrated downward trend in hydroxyapatite crystals size although it was not significantly different from the C group (P>0.05). The 1500 mg/kg BW dose of CSN1S2 administration could improve the hydroxyapatite crystal size of diabetes mellitus rats to the value of the control group (P>0.05).

DISCUSSIONS

The resorption of bone tissue and formation of new bone tissue are the two antagonistic processes in bone remodeling regulated by osteoclasts and osteoblasts, respectively. If the activity of osteoclasts is faster than osteoblasts, the bones will have lower mineral density that lead to higher risk of bone fracture (Dimitriou et al., 2011). T2DM has direct negative effects on bone cells leading to risk factors for fractures. Previous study reported that T2DM individuals had an increased risk of hip fracture (Tebé et al., 2019). One of the causes of

![Figure 5. The X-Ray diffraction of hydroxyapatite crystals size was analyzed by XRD.
   a) P<0.05 in comparison with control group; b) P<0.05 in comparison with CM375; c) control rat group receiving 0 mg/kg BW of CSN1S2 protein; CM375: control rat group receiving 375 mg/kg BW of CSN1S2 protein; CM750: control rat group receiving 750 mg/kg BW of CSN1S2 protein; CM1500: control rat group receiving 1500 mg/kg BW of CSN1S2 protein; DMM375: T2DM rat group receiving 375 mg/kg BW of CSN1S2 protein; DMM750: T2DM rat group receiving 750 mg/kg BW of CSN1S2 protein; DMM1500: T2DM rat group receiving 1500 mg/kg BW of CSN1S2 protein.

![Figure 6. The mechanism of DM rat Bone Formation on Bone Morphogenetic Protein Signaling repaired normally by Caprine milk CSN1S2 protein.]
bone damage in diabetic people is the increase in AGEs accumulation due to the dysregulation of blood level (Brownlee, 2001). Other study has demonstrated increased AGEs content in the bone tissue of T2DM rat model as well (Campbell et al., 2016). In this study, serum AGEs increased significantly in the DM group compared to control. This showed that hyperglycemia in diabetes mellitus triggered the production of AGEs in the serum and a decrease in sRAGE. This study is consistent with previous findings that AGEs increased in T2DM, while sRAGE decreased (Abdulle et al., 2019). The formation of AGEs in bone matrix will increase the rate of apoptosis of osteoblasts and its precursor cells (Pike et al., 2019).

The osteoblasts differentiation is regulated by several growth factors and cytokines. BMP2, a member of BMP family, is an important osteoinductive growth factor (Sun et al., 2015). BMP2 promotes the proliferation and osteogenic differentiation of mesenchymal stem cells by regulating RUNX2 and OSX expression. RUNX2 and OSX are the growth factors that are expressed during and after differentiation into osteoblasts (Nakashima et al., 2002). BMP2 is known to control the RUNX2 expression and functions through Smad signaling (Wu, C-J, Lu, 2008). The downstream of RUNX2 during osteoblast differentiation is OSX (Nakashima et al., 2002). However, other studies revealed that OSX expression can be dependent on or independent of RUNX2 activity (Sinha & Zhou, 2013).

Previous study reported that the RUNX2 expression was suppressed in high-fat and high-glucose conditions (Wu et al., 2019). High glucose condition and AGEs treatment in human osteoblasts demonstrated reduced expression of RUNX2 and OSX (Miranda et al., 2016). The reduced RUNX2 and OSX protein expression were observed in the mouse stromal cell line ST2 (differentiated into osteoblast-like cells) treated with AGEs as well (Okazaki & Yamaguchi, 2012). Our data in Fig. 6 showed that BMP signaling stimulate the regulation of bone formation in diabetic rats by Caprine milk CNS1S2 protein that had a high level of serum AGEs also had the down-regulated expression of BMP2, RUNX2, and OSX. Moreover, the number of osteoblasts and osteoclasts were decreased and increased, respectively. Interestingly, this Caprine CNS1S2 protein treatment decreased AGEs not only in control rats but also in diabetic rats. The reduction of serum AGEs level was along with the up-regulated expressions of BMP2, RUNX2 and OSX in CNS1S2 protein-treated diabetic rats. As previously stated, those osteogenic genes expressions are correlated to the osteoclast and osteoblast number, both of which are types of bone cells that keep forming and reforming bone tissue. The administration of CNS1S2 protein at the dose of 375 and 750 mg/kg BW was able to reduce the osteoclast number in diabetic rats and increase the osteoblast differentiation both in control and diabetic rats. Therefore, the Caprine CNS1S2 protein may play a role in bone formation through induction of the BMP2, RUNX2, and OSX expression.

Caspase-3 is a critical enzyme for apoptosis and cell survival. An inappropriate apoptosis of osteoblasts/osteocytes accounted for the imbalance of bone remodeling in osteoporosis. In diabetes condition, the Caspase-3 expression was getting higher than the control (He et al., 2018). In this study, the diabetic rats had an elevated Caspase-3 expression. The 375, 750, and 1500mg/kg BW of CNS1S2 protein doses were able to weaken the Caspase-3 expression in diabetic rats.

The results of this study suggest that CNS1S2 protein is a smart molecule with its anti-glycation properties. The anti-glycation mechanism occurs through the increasing of sRAGE that will bind to AGEs, therefore serum AGEs will change to a lower level. Our previous study showed that the CNS1S2 protein acted as AGEs-RAGE inhibitor that disrupted the signaling transduction cascade (Fatchiyah et al., 2015). This study proves that CNS1S2 may be a candidate for a new anti-glycation molecule.

The change of different directions and in different intensity of bone is able to change loading patterns that can alter structural density and increase the degree of structural orientation (Osterhoff et al., 2016). The mesostructure of control rats demonstrated rod-like trabeculae with minimal holes in control rat (Noor & Setiawan, 2013). The CNS1S2 treatment triggered the thickening of trabecular bone wall and granule formation in control rat. Our research indicated that the administration of CNS1S2 induced the bone growth. This finding was supported by the hydroxyapatite crystal size, which tended to increase in CNS1S2-treated control rat. Meanwhile,

---

**Table 1. The histomorphometry of head femoral bone in control and treatment groups measured by SEM and BoneJ software.**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>C</th>
<th>CM375</th>
<th>CM750</th>
<th>CM1500</th>
<th>DM</th>
<th>DMM375</th>
<th>DMM750</th>
<th>DMM1500</th>
</tr>
</thead>
<tbody>
<tr>
<td>BV</td>
<td>556.243 ±</td>
<td>445.586 ±</td>
<td>474.274 ±</td>
<td>561.925 ±</td>
<td>688.414 ±</td>
<td>517.189 ±</td>
<td>598.666 ±</td>
<td>758.884 ±</td>
</tr>
<tr>
<td></td>
<td>7.895</td>
<td>5.814 ±</td>
<td>43.017 ±</td>
<td>6.268 ±</td>
<td>0.847 ±</td>
<td>2.159 ±</td>
<td>130.154</td>
<td>7.026 ±</td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>0.665 ±</td>
<td>0.533 ±</td>
<td>0.567 ±</td>
<td>0.674 ±</td>
<td>0.824 ±</td>
<td>0.619 ±</td>
<td>0.717 ±</td>
<td>0.919 ±</td>
</tr>
<tr>
<td></td>
<td>0.009</td>
<td>0.026 ±</td>
<td>0.051 ±</td>
<td>0.025 ±</td>
<td>0.025 ±</td>
<td>0.022 ±</td>
<td>0.156 ±</td>
<td>0.068 ±</td>
</tr>
<tr>
<td>Tb.Th (µm)</td>
<td>2.834 ±</td>
<td>1.862 ±</td>
<td>1.534 ±</td>
<td>3.127 ±</td>
<td>3.940 ±</td>
<td>2.794 ±</td>
<td>2.717 ±</td>
<td>3.121 ±</td>
</tr>
<tr>
<td></td>
<td>0.045</td>
<td>0.069</td>
<td>0.598 ±</td>
<td>0.030 ±</td>
<td>0.003 ±</td>
<td>0.054 ±</td>
<td>0.722 ±</td>
<td>0.016 ±</td>
</tr>
<tr>
<td>Tb.Sp (µm)</td>
<td>0.368 ±</td>
<td>0.788 ±</td>
<td>0.248 ±</td>
<td>0.310 ±</td>
<td>0.837 ±</td>
<td>0.289 ±</td>
<td>0.336 ±</td>
<td>0.312 ±</td>
</tr>
<tr>
<td></td>
<td>0.022</td>
<td>0.004 ±</td>
<td>0.029 ±</td>
<td>0.023 ±</td>
<td>0.002 ±</td>
<td>0.001 ±</td>
<td>0.130 ±</td>
<td>0.007 ±</td>
</tr>
<tr>
<td></td>
<td>0.313</td>
<td>0.005 ±</td>
<td>0.294 ±</td>
<td>0.008 ±</td>
<td>0.052 ±</td>
<td>0.114 ±</td>
<td>0.337 ±</td>
<td>0.006 ±</td>
</tr>
</tbody>
</table>

Note: Data was presented as mean ± standard of deviation. BV: bone volume; BV/TV: bone volume/trabecular volume; Tb.Th: trabecular thickness; Tb.Sp: trabecular spacing; SMI: structure model index; %: percentage; µm: micromolar; C: control (healthy rats without any treatment); CM375: healthy rats received CSN1S2 at dose of 375mg/kg BW; CM750: healthy rats received CSN1S2 at dose of 750 mg/kg BW; CM1500: healthy rats received CSN1S2 at dose of 1500 mg/kg BW treatment; DM: type 2 diabetic rats; DMM375: type 2 diabetic rats supplemented with CSN1S2 at dose of 375 mg/kg BW; DMM750: type 2 diabetic rats supplemented with CSN1S2 at dose of 750 mg/kg BW; DM1500: type 2 diabetic rats supplemented with CSN1S2 at dose of 1500 mg/kg BW; P<0.05 in comparison with control group; P<0.05 in comparison with diabetes mellitus rat group; P<0.05 in comparison with DMM750 group.
the diabetes mellitus rat showed granules thickening that filled the trabecular bone holes. The administration of CSN1S2 at the dose of 750 and 1500 mg/kg BW in diabetic rat was able to improve the granules and minimize the holes as in control rat. It indicated that CSN1S2 treatment could restore the trabecular bone mesostructure of diabetic rats closer to the healthy bone structure. This study extends the previous findings that revealed the bone anabolic properties of CSN1S2 (Fatchiyah & Setiawan, 2015) through the mechanism of RAGE receptor modulation (Bia et al., 2015), as well as pre-osteoblast cell proliferation modulation (Chotimah et al., 2015).

The BV, BV/TV, and Tb.Th of CSN1S2-treated control rats (CM375 and CM750) decreased. This finding was in agreement consistent with our previous findings that CSN1S2 caused decreases in these parameters (Fatchiyah et al., 2015). The 1500 mg/kg BW of CSN1S2-treated control rats showed a rise in Tb.Th and a significant decrease in Tb.Sp and SMI compared to controls. This indicates that the best anabolic effect occurred in the 1500 mg/kg BW of CSN1S2 administration. The 1500 mg/kg BW of CSN1S2 increases the trabecular thickness, suppresses porous, and changes rod-like structures into plate-like.

In diabetes mellitus rats, there was an increase in BV, BV/TV, Tb.Th, Tb.Sp and a significant decrease in SMI compared to control rats ($P<0.05$). This showed that changes in volume of bone, percentage of bone volume to total volume, trabecular thickness, and increased porosity had taken place in diabetes mellitus. The rod-like structures alteration to plate-like was induced by hyperglycemia. The possible mechanism happens through the glycation reaction that triggers oxidative stress and inhibits bone mineralization (Hofbauer et al., 2007). Hyperglycemia affects directly through a decrease in formation and motility of osteoclast so that there will be difficulties in reaching the micro-fractures and repairing the osteoclasts. Hyperglycemia decreases the number of osteoblasts as well (Willett et al., 2014).

The main limitation of this study is the unchanged blood glucose level of T2DM rats after a Caprine CSN1S2 protein treatment. The CSN1S2 protein was not able to lower the high blood glucose level of T2DM rats in 28 days of treatment. However, CSN1S2 protein reduced the serum AGES level of T2DM rats implicated in the un-regulated expressions of BMP2, RUNX2, and OSX. This indicates that CSN1S2 does not have a hypoglycemic effect, but works to inhibit the formation of AGES, modulation of osteoblast signals, and repair of mesostructure and bone crystals. The absence of this hypoglycemic effect makes CSN1S2 a smart molecule to avoid potential hypoglycemia as a side effect in the treatment of diabetic patients (He et al., 2019).

The trabecular repairing mechanism in DM rat was showed by the ability of Caprine Milk CSN1S2 protein to decrease the AGES accumulation, the mechanism related with bone morphogenetic protein (BMP) signaling pathway for osteoblast related bone formation. Improvement of bone formation was indicated by normalizing of trabecular thickness, covering of the trabecular surface by granules, decreasing trabecular porosity, and improving the structural index towards the rod-like trabeculae. Nano-structurally, this mesostructure alteration involves at least a change in hydroxyapatite crystals. The 375, 750, and 1500 mg/kg BW of Caprine CSN1S2 protein administration in diabetic rats were able to repair bone, in the form of Tb.Th controlling similar to the C group. The porosity improvement was found in diabetic rats receiving 750 and 1500 mg/kg BW of CSN1S2, reaching a value comparable to the control group. This indicates that both of CSN1S2 doses can induce bone regeneration in the form of controlling values in healthy bones. This is supported by the change of SMI value of diabetic rats close to the value in healthy rats. Administration of high dose CSN1S2 at T2DM rats leads to improvement of SMI value compared to the others. This result is consistent with previous research suggesting that Caprine CSN1S2 protein acts as an anti-osteoporosis in rat model of rheumatoid arthritis (Fatchiyah et al., 2015). This study proposes that the Caprine CSN1S2 protein has a role as an anti-osteoporosis in T2DM rat model via bone morphogenetic protein (BMP) pathway.

CONCLUSIONS

The Caprine CSN1S2 protein has an osteoprotective effect against the T2DM rats through the inhibition of glycation pathway and the improvement of bone mesostructure and histomorphometry. Thus, Caprine CSN1S2 protein can be used as an alternative nutrition in preventing T2DM complications.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Author Contributions

Fatchiyah Fatchiyah and Bambang Setiawan contributed to the conception and design of the experiments, acquisition of data, analysis, and data interpretation, drafting article, critically revising the article and final approval of the version to be published. Tomohiko Sasase and Takeshi Ohta contributed to data interpretation and reviewing the manuscript.

Acknowledgments

We give thanks to Dr. drg. Arif Rachman, MM., MTr., Hanla., Sp.Pros., at Dr. Ramelan Naval Hospital, Surabaya, and Dr. dr. Indri Laksmi Putri, Sp.BP-RE (KKF) at Airlangga University Hospital, Surabaya for providing the BMP2, RUNX2, and OXs antibodies. Gratitude sent to Anna Safitri, Ph.D (UB) for comments on the manuscript, Rista Nikmatu Rochmah and Hazna Noor Meidina for laboratory assistant. We thank the Molecular Biology Laboratory of Biosains Institute, Brawijaya University for providing the laboratory facilities.

REFERENCES


Vol. 68
T2DM rat femoral bone achieved by anti-osteoporosis of caprine CSN1S2 protein

273

Author Contributions

Fatchiyah Fatchiyah and Bambang Setiawan contributed to the conception and design of the experiments, acquisition of data, analysis, and data interpretation, drafting article, critically revising the article and final approval of the version to be published. Tomohiko Sasase and Takeshi Ohta contributed to data interpretation and reviewing the manuscript.

Acknowledgments

We give thanks to Dr. drg. Arif Rachman, MM., MTr., Hanla., Sp.Pros., at Dr. Ramelan Naval Hospital, Surabaya, and Dr. dr. Indri Laksmi Putri, Sp.BP-RE (KKF) at Airlangga University Hospital, Surabaya for providing the BMP2, RUNX2, and OXs antibodies. Gratitude sent to Anna Safitri, Ph.D (UB) for comments on the manuscript, Rista Nikmatu Rochmah and Hazna Noor Meidina for laboratory assistant. We thank the Molecular Biology Laboratory of Biosains Institute, Brawijaya University for providing the laboratory facilities.


Wu M, Chen G, Li YP (2016) TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 4: 1–18 https://doi.org/10.1038/boneres.2016.9
